Genetic prediction of antihyperglycemic drug targets and risk of epilepsy: a mendelian randomisation study

Table 1 MR Analysis of anti-glucose drug target genes and epilepsy

Stage	Target gene	Method	Nsnp	Beta	Pval	Q	Ple	R2	F	Drugs and Pharmacological action
Discovery	ETFDH	Inverse variance weighted (fixed effects)	7	0.019	0.0091	0.24	0.61	0.68	19.10	Metformin (Yes inhibitor)
Replication	ETFDH	Inverse variance weighted (fixed effects) Weighted median	5 5	0.130 0.095	0.0001 0.0360	0.55	0.33	0.23	12.20	Metformin (Yes inhibitor)
Discovery	CYP21A2	Inverse variance weighted	2	0.029	0.0166	NA	NA	0.19	20.17	Levoketoconazole (No)
Replication	CYP21A2	Inverse variance weighted (fixed effects)	5	0.055	0.0451	0.07	0.24	0.24	25.92	Levoketoconazole (No)
Discovery	CYP2D6	Inverse variance weighted (fixed effects) Weighted median	4 4	-0.017 -0.019	0.0253 0.0324	0.78	0.56	0.54	27.60	Dapagliflozin (No) Phenformin (Unkonw)
Replication	CYP2D6	Inverse variance weighted (fixed effects)	13	-0.023	0.0460	0.69	0.78	0.90	12.56	Nateglinide (Unkonw) Rosiglitazone (Unkonw) Alogliptin (Unkonw)

Note: Stage refers to our MR Research stage, which is divided into discovery set and validation set. method refers to the meta method we used; Nsnp refers to the number of instrumental variables used; Beta refers to the effect size in the MR Analysis; and P-val refers to the statistical significance of the MR Analysis. Q refers to the significance of the heterogeneity test and Ple refers to the significance level of the pleiotropy test in the MR Analysis. R2 refers to the degree to which the instrumental variable explains the exposure. F is the F-test statistic. Drugs and Pharmacological action refer to the drugs related to the target genes of anti-glucose drugs and the pharmacological effects between them

ISSN: 2050-6511